MacroGenics, Inc.
NASDAQ:MGNX · NASDAQ Global Select
+$0.08 today
Vol 0.96M · Avg 0.98M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$74.6M -11.4% | -$67.0M -639.3% | -$9.1M +92.4% | -$119.8M +40.7% | -$202.1M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $5.5M -26.7% | $7.5M -21.8% | $9.6M -18.7% | $11.9M +5.4% | $11.3M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $14.3M -51.5% | $29.4M +60.2% | $18.4M -10.1% | $20.4M -11.6% | $23.1M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$28.3M -2135.3% | $1.4M -97.4% | $53.3M +969.8% | -$6.1M -134.9% | $17.6M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$9.1M -249.6% | $6.1M -86.8% | $45.9M +200.0% | -$45.8M -461.0% | $12.7M | $592.6M | $1.3B | $626.2M |
| Inventory | -$7.9M -261.5% | -$2.2M -1051.3% | $230.0K +318.2% | $55.0K +100.9% | -$6.4M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$280.0K +81.7% | -$1.5M -219.4% | $1.3M +111.8% | -$10.9M -252.4% | $7.1M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$11.1M -1068.6% | -$948.0K -115.9% | $6.0M -88.2% | $50.5M +1110.7% | $4.2M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $2.1M +105.3% | -$39.8M +73.6% | -$150.5M -2371.1% | $6.6M +4.6% | $6.3M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$81.0M -18.5% | -$68.4M +12.6% | -$78.2M +10.1% | -$87.0M +39.5% | -$143.8M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$1.9M +48.4% | -$3.7M -110.1% | -$1.8M +51.3% | -$3.6M +41.6% | -$6.2M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $11.0K | $0 -100.0% | $64.0K | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$208.3M -169.9% | -$77.2M +67.8% | -$239.7M -98.7% | -$120.6M +47.8% | -$231.2M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $96.1M -49.4% | $190.0M +17.8% | $161.3M -17.3% | $194.9M -2.9% | $200.8M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 -100.0% | $40.2M | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$114.1M -176.4% | $149.3M +286.4% | -$80.1M -213.2% | $70.7M +293.2% | -$36.6M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 +100.0% | -$157.0K | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $129.0K -96.2% | $3.4M +193.8% | $1.2M +7.7% | $1.1M -99.1% | $117.8M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $69.4M +7127.6% | $960.0K -99.4% | $149.3M +25919.0% | $574.0K -88.4% | $5.0M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $69.5M +7141.0% | $960.0K -99.4% | $150.4M +8963.4% | $1.7M -98.6% | $122.8M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$125.6M -253.4% | $81.9M +1132.8% | -$7.9M +45.6% | -$14.6M +74.7% | -$57.7M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$83.0M -15.1% | -$72.1M +9.9% | -$80.0M +11.7% | -$90.6M +39.6% | -$150.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$305.31M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$259.77M
Shattuck Labs, Inc.
NASDAQ:STTK
$232.19M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$208.69M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$157.57M
InflaRx N.V.
NASDAQ:IFRX
$129.66M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$125.61M
Coya Therapeutics, Inc.
NASDAQ:COYA
$89.31M
Clene Inc.
NASDAQ:CLNN
$61.18M
Context Therapeutics Inc.
NASDAQ:CNTX
$56.22M
SEC Filings
Recent regulatory filings
No filings found.
Does MGNX generate free cash flow?
MacroGenics, Inc. (MGNX) generated -$82,954,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does MGNX produce?
Operating cash flow was -$81,040,000.00, before capital expenditures of $1.91M.
Explore More
Continue the stock analysis
Jump to another research area for this company.